10-Q quarterly report · filed Nov 12, 2026

Spero Therapeutics Inc (SPRO) Q3 2026 10-Q Quarterly Report

Short answer

Spero Therapeutics Inc (SPRO) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$44M.

Q3 2026 key financials · XBRL

Revenue
$0
Net income
−$44M
−499.8% YoY · −363.5% QoQ
EPS (diluted)
−$0.77
−492.3% YoY · −381.3% QoQ

Source: XBRL data from the Spero Therapeutics Inc (SPRO) Q3 2026 10-Q on SEC EDGAR. USD.

Spero Therapeutics Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0 vs $5.442M YoY, reflecting no grant or collaboration revenue
  • Net loss $44.278M vs $7.382M YoY, operating loss $41.913M vs $7.916M
  • Worst-performing line: grant revenue $0 vs $2.394M, collaboration revenue $0 vs $3.048M
  • Cash $107.9M; operating cash use $32.098M, financing provided $99.761M from milestone and royalty financing
  • SP001 Phase 2 IgG4-RD trial expected Q2 2027, subject to FDA IND clearance; funding projected into second half of 2029

Risk Factors

  • New lead-candidate dependence: July 8, 2026 Innovent Agreement shifted focus to SP001, now the only clinical-stage candidate
  • Most material update: Utebzi FDA approval and SPR206/SPR720 termination increased reliance on SP001 development and GSK commercialization
  • Regulatory risk: May 2026 House draft report could bar FDA consideration of China-generated clinical data supporting SP001’s IND
  • Competitive risk: SP001 faces approved UPLIZNA and multiple IgG4-related disease candidates in development
  • Liquidity risk: $105.0 million HCRx Notes limit retained GSK proceeds to 35% after repayment terms

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Spero Therapeutics Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.